Lin Deng

Scientist in pulmonary vascular diseases

[Lin Deng @dlljj]

@MedComm_MC Congratulations

[Lin Deng @dlljj]

Glad to share that our commentary on the recent Science article finally been published. An exciting step forward in understanding the metabolic and inflammatory basis of PAH.
https://t.co/P9OdRmgm9U

[Lin Deng @dlljj]

Do you remember when you joined X? I do! #MyXAnniversary

[Katalin Susztak @KSusztak]

Multi-omic profiling reveals age-related immune dynamics in healthy adults | ⁦@Nature⁩ https://t.co/9QxWXom2tL

[Imtiaz Mahmood @ImtiazMadmood]

Scientists in Israel have made a medical breakthrough by 3D-printing the world’s first functioning human heart using a patient’s own cells. Developed at Tel Aviv University, this tiny heart is about the size of a rabbit’s and includes real blood vessels, chambers, and working tissue. It can even contract and pump fluid on its own.

The process begins by transforming fat cells into stem cells, which are then shaped into cardiac tissue. This lab-grown heart is still small, but it proves that creating living organs is no longer just science fiction. The research opens the door to growing fully functional human organs in the lab.

The long-term goal is to print full-sized hearts for transplantation, perfectly matched to patients so there is no risk of rejection. If successful, this technology could solve the global organ shortage, offering patients new hearts made from their own cells without long waiting lists.

This breakthrough demonstrates the power of regenerative medicine and 3D-printing technology. It represents hope for millions of patients with heart disease and could redefine the future of organ transplantation. The heart of medicine is beating stronger than ever.

[Lin Deng @dlljj]

@PullamsettiL @jlugiessen @CPI_ExStra @chansteve73 @KeYuan_BCH @Savai_Lab @dzlacademy Congrats,Looking forward another one

[Laurent Bertoletti @LaurentBertole1]

❓ Do anticoagulants really improve survival in pulmonary arterial hypertension (#PAH)?
Our study does shows that routine anticoagulation does not confer an overall survival benefit (HR: 0.997; 95% CI: 0.84-1.18).
The discussion is open! 👇

[Trends Cell Biology @TrendsCellBio]

Organelle-specific signaling of cGAS–STING https://t.co/jLKd2kUL7j

[Lin Deng @dlljj]

Our research letter is online @AJRCMB
IGFBP7 Contributes to EndMT and Serves as Biomarker for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. Really appreciated the valuable support from @sbonnet2 and @Olivier Boucherat.
@atscommunity
https://t.co/Kma4DD8M5p

[Nature Medicine @NatureMedicine]

RESEARCH

Based on 337 human kidney & plasma samples, the authors generate the first kidney pQTL dataset & explore novel risk loci relevant for cardio-kidney-metabolic health.

#metabolism #liver #proteomics

https://t.co/PcqeNx2cVZ

[nature @Nature]

Nature research paper: NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

https://t.co/oljbkCdBlA

[Journal of Experimental Medicine @JExpMed]

Insights from Mahfoud & Padera: Geng et al. (https://t.co/5jIMgzAAwY) show that LEC S1P/S1PR1 signaling plays a role in mesenteric TLS formation in the absence of subclinical inflammation and, importantly, is a key regulator of lymphatic valve development. https://t.co/hga5Da4Km9

[Nature Reviews Drug Discovery @NatRevDrugDisc]

A first-in-class drug for the inflammatory lung disease bronchiectasis that could be approved by the FDA in the next few weeks is anticipated to have peak sales of more than $4 billion. Find out more in this news story in the July issue https://t.co/9Q6hCARMy0

[Lin Deng @dlljj]

@SobanUmar @UCLAAnes @UCLAHealth @dgsomucla @UCLA Congratulations, super news 🎉

[Lin Deng @dlljj]

@MingxiaGu @CellCellPress @CuSTOM_CCHMC @UCLAstemcell Congratulations

[Bruno Ramos-Molina, PhD @Brunorm84]

Synergistic effects of CCR2 inhibitor and TGF-β type I receptor kinase inhibitor combination in #MASH @Els_ENDO https://t.co/4CapUJZKif

[Lin Deng @dlljj]

@sbonnet2 @IUCPQ @universitelaval @facmedUL @ATS_PC @3CPRCouncil @PVRI Good to see LTBP2 and IGFBP7 levels are significantly changed in this PAH cohort.

[David Sinclair @davidasinclair]

An antibody directed to the NAD-degrading enzyme CD38 in mice restores metabolic fitness, improves cognitive performance & lowers neuroinflammation
https://t.co/6BHaD9zJqk

[Montani David @Montanidavid]

Happy to share our article published in AJRCCM @ATSBlueEditor, analyzing safety and efficacy of sotatercept in #PAH according to genetic status.

@pulmotension @InsermU999 @SPLF_SocPneumo @HTaPFrance

https://t.co/iLBfFIjLqW

[Cell Metabolism @Cell_Metabolism]

New! Online now: Nicotinic acid riboside maintains NAD+ homeostasis and ameliorates aging-associated NAD+ decline https://t.co/a3HUssZRQI